Mainstay Medical
-
Spine
Mainstay Medical Announces the Completion of All Implants in the ReActiv8-B Study
July 09, 2018 DUBLIN–(BUSINESS WIRE)–Regulatory News: Mainstay Medical International plc (“Mainstay” or the “Company”, Euronext Paris: MSTY.PA and Euronext Dublin: MSTY.IE),…
Read More » -
Spine
Mainstay Medical Announces CFO Transition
May 22, 2018 DUBLIN–(BUSINESS WIRE)– Mainstay Medical International plc (“Mainstay” or the “Company”, Euronext Paris: MSTY.PA and Euronext Dublin: MSTY.IE), a…
Read More » -
Financial
Mainstay Medical Announces Half Year Financial Results
September 05, 2017 Mainstay Medical International plc (Mainstay or the Company, Euronext Paris: MSTY.PA and ESM of the Irish Stock Exchange: MSTY.IE),…
Read More » -
Neuro
Mainstay Medical Announces CEO Leadership Transition
Dublin – Ireland, 5 September 2017 – Mainstay Medical International plc (“Mainstay” or the “Company”, Euronext Paris: MSTY.PA and ESM…
Read More » -
Financial
Mainstay Medical to seek further funding as full-year losses mount
Aug 24, 2017 – Charlie Taylor Dublin-listed Mainstay Medical, a company that is targeting chronic back pain with an implantable device, is…
Read More » -
Hospitals
Mainstay Medical’s ReActiv8-B Clinical Trial Passes Mid-point
August 03, 2017 Mainstay Medical International plc (“Mainstay” or the “Company”, Euronext Paris: MSTY.PA and ESM of the Irish Stock Exchange:…
Read More »